Moonlake Immunotherapeutics
+$416.1M
Net Activity
Institutions Holding
149
Popularity Rank
#3567
Avg Weight
0.33%
Total Value
$1.2B
149 institutions currently hold MLTX, with 85 net buyers and 69 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
69
Net Buying Institutions
85
Top 5 by Value
+$626.5M
Total Buy Value
$529.1M
Total Sell Value
85
Net Buyers
69
Net Sellers
2
Filings (90d)
$5.85M
Total Est. Value
300K shares
Planned Shares
| Filer | Filing Date | Est. Value |
|---|---|---|
| Santos da Silva Jorge | 2026-06-30 | $3.00M |
| Reich Kristian | 2026-06-15 | $2.85M |
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
1
Active 5%+ Holders
| Reporting Person | Type | Filing Date | % of Class |
|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 13D/A | 2026-06-29 | 19.7% |
1
Filings (14d)
Underwriters of MoonLake Immunotherapeutics' public offering exercised their option to purchase an additional 1.5 million ordinary shares on July 10, 2026, bringing in extra gross proceeds of $30 million. The sale closed on July 14.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter